Skip to main content
. 2021 Apr 7;20:78. doi: 10.1186/s12933-021-01266-x

Fig. 1.

Fig. 1

SGLT2i reduce the risk of hospitalization for heart failure in large randomized controlled trials. With SGLT2i therapy, the reduction in risk of hospitalization for heart failure was consistent and significant across different patients. CI, confidence interval; NA, not available